HDAC9 and cancer: Clinically, several FDA-approved HDAC inhibitors, including suberoylanilide hydroxamic acid (SAHA), belinostat, romidepsin, and givinostat, have shown efficacy in a range of cancers and certain genetic neuromuscular disorders.